Early stage Scottish drugs company PharmaKrysto,has completed an exclusive global licensing deal with Rutgers University in New Jersey for a potentially revolutionary compound to treat people suffering from a kidney disease.

PK10 is a treatment for cystinuria is an inherited disease that causes large, painful and debilitating crystals of amino acid to form in the kidneys.

Edinburgh-based PharmaKrysto has also been granted a key clearance by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).  

The company is now receiving support for a fundraising round to prepare for patient trials.

Chief executive Julian Howell said: “These three events represent the achievement of major milestones for PharmaKrysto as we seek to develop this exciting new treatment for people with cystinuria.”